Publications

FT500

2020 SITC Poster

Preliminary results of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid tumors

Science Translational Medicine 2020; 12(568).

iPSC-Derived NK Cells Maintain High Cytotoxicity and Enhance In Vivo Tumor Control in Concert with T Cells and Anti–PD-1 Therapy

J Clin Invest. 2018; 128(10): 4654–4668.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

British Journal of Cancer. 2018; 118: 9–16.

Mechanisms of resistance to immune checkpoint inhibitors

Nature Communications. 2017; 8: 1136.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation
FT516

2021 ASH Abstract

Phase I Study of FT516, an Off-the-Shelf, iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed / Refractory B-Cell Lymphoma

Blood. 2020; 135 (6): 399–410.

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity
FT536

2022 ASGCT Presentation

FT536: A First-of-Kind, Off-the-Shelf CAR-iNK Cell Product Candidate for Solid Tumors Designed to Specifically Target MICA/B Stress Proteins and Overcome Mechanisms of Tumor Evasion

2021 SITC Abstract

FT536 Path to IND: Ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy

Cancer Immunol Res 2020; 8:769–80.

Inhibition of MICA and MICB Shedding Elicits NK-Cell–Mediated Immunity against Tumors Resistant to Cytotoxic T Cells
FT596

2021 ASH Abstract

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

2021 ASH Abstract

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed / Refractory B-Cell Lymphoma

New England Journal of Medicine. 2020; 382: 545–53.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

2019 ASH Abstract

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
FT538

Cancer Stem Cell Publication

Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy

2021 SITC Abstract

Off-the-shelf, engineered iPSC-derived NK cells mediate potent cytotoxic activity against primary glioblastoma cells and promote durable long-term survival in vivo

2020 ASH Poster Presentation – Manufacturing

cGMP Mass Production of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered Natural Killer Cell Cancer Immunotherapy Derived from a Clonal Master Induced Pluripotent Stem Cell Line

2020 ASH Poster Presentation – Clinical

A Phase I Study of FT538, a First of Kind, Off the Shelf, Multiplexed Engineered, iPSC Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma

2019 ASH Abstract

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab
FT576

2020 ASH Poster Presentation

FT576: Multi specific Off the Shelf CAR NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self Fratricide and Optimized mAb Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

2019 ASH Abstract

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and BCMA for the Treatment of Multiple Myeloma
FT573

2022 AACR Poster

FT573: Preclinical Development of Multiplexed-Engineered iPSC-derived NK Cells Expressing a Novel Camelid Nanobody Chimeric Antigen Receptor (CAR) Targeting pan-Cancer Antigen B7-H3
FT819

2021 ASH Abstract

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

2019 ASH Abstract

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Nature Medicine. 2019; 25: 82–88.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Nature. 2017; 543: 113–117.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
iPSC Product Platform

2022 AACR Posters

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy
Chimeric CD3 Fusion Receptors Expressed on iPSC-derived Universal TCR-less CAR-T and -NK Cells Synergize with Bispecific Engagers to Enhance Antitumor Activity and Limit Antigen Escape
Novel Combination of iPSC-derived Dual Dual -CAR NK Cells with CD16 Fc Receptor for Multi-antigen Targeting of Multiple Myeloma to Overcome Clonal Resistance and Antigen Escape
Multiplexed-engineered, iPSC-derived T Cells Expressing Three Unique Targeting Modalities Address Tumor Heterogeneity and Antigen Escape
Detection of Genetically Engineered iPSC-derived Natural Killer Cells in Blood and Tissue

2022 ASGCT Posters

Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications
Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies
Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors
Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy
10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization
Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells
iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy

2021 SITC Abstract

Synthetic redirection of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors
Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors

2021 ASH Abstract

Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma
Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection
Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Stem Cell Reporst

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells